DEFERASIROX - Generic Drug Details

What are the generic drug sources for deferasirox and what is the scope of freedom to operate?

Deferasirox is the generic ingredient in four branded drugs marketed by Alkem Labs Ltd, Amneal, Annora Pharma, Aucta, Aurobindo Pharma, Cipla, MSN, Pharmobedient, Teva Pharms Usa, Novartis, Actavis Elizabeth, Alembic, Bionpharma, Glenmark Speclt, Sun Pharm, Torrent, Zydus Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Jubilant Generics, Piramal, Stevens J, and Novartis Pharms Corp, and is included in thirty-eight NDAs. There is one patent protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Deferasirox has sixty-eight patent family members in forty-three countries.

There are twenty drug master file entries for deferasirox. Twenty-two suppliers are listed for this compound.

Summary for DEFERASIROX

International Patents:	68
US Patents:	1
Tradenames:	4
Applicants:	23
NDAs:	38
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	112
Clinical Trials:	101
Patent Applications:	2,545
Drug Prices:	Drug price trends for DEFERASIROX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DEFERASIROX
What excipients (inactive ingredients) are in DEFERASIROX?	DEFERASIROX excipients list
DailyMed Link:	DEFERASIROX at DailyMed

See drug prices for DEFERASIROX

Recent Clinical Trials for DEFERASIROX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	PHASE2
University of Michigan Rogel Cancer Center	PHASE2
National Institutes of Health (NIH)	PHASE2

See all DEFERASIROX clinical trials

Pharmacology for DEFERASIROX

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for DEFERASIROX

V03AC	Iron chelating agents
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for DEFERASIROX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JADENU	Tablets	deferasirox	180 mg	206910	1	2016-04-21
JADENU	Tablets	deferasirox	90 mg and 360 mg	206910	1	2015-10-19
EXJADE	Tablets for Suspension	deferasirox	125 mg, 250 mg, and 500 mg	021882	1	2011-10-28

US Patents and Regulatory Information for DEFERASIROX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Speclt	DEFERASIROX	deferasirox	TABLET, FOR SUSPENSION;ORAL	209433-003	Jan 6, 2020	AB	RX	No	No
Msn	DEFERASIROX	deferasirox	GRANULE;ORAL	214650-002	Mar 17, 2021	AB	RX	No	No
Stevens J	DEFERASIROX	deferasirox	TABLET;ORAL	210727-003	Jun 15, 2020		DISCN	No	No
Torrent	DEFERASIROX	deferasirox	TABLET, FOR SUSPENSION;ORAL	209426-001	Nov 5, 2024		DISCN	No	No
Piramal	DEFERASIROX	deferasirox	TABLET;ORAL	212995-001	Dec 30, 2019	AB	RX	No	No

Expired US Patents for DEFERASIROX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,465,504
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,596,750
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882-002	Nov 2, 2005	6,465,504

EU/EMA Drug Approvals for DEFERASIROX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for DEFERASIROX

Country	Patent Number	Title	Estimated Expiration
South Korea	101925671
Ecuador	SP15042897
Peru	20151600
Lithuania	2964202
Denmark	3124018

Supplementary Protection Certificates for DEFERASIROX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	PA2007001	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
0914118	PA2007001,C0914118	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
0914118	SPC/GB07/002	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
0914118	C00914118/01	Switzerland		PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005

Market Dynamics and Financial Trajectory for Deferasirox

Last updated: January 29, 2026

Executive Summary

Deferasirox, an oral iron chelator branded as Exjade (original) and Jadenu (new formulation), is a critical therapy for managing chronic iron overload in patients requiring repeated blood transfusions. Its market has shown significant growth driven by increasing prevalence of transfusion-dependent conditions, advancements in drug formulations, and expanding geographical reach. This report examines the current market landscape, key financial metrics, competitive positioning, regulatory environment, and forecasted trends for Deferasirox.

---

What is Deferasirox?

Deferasirox is a selective oral iron chelator developed by Novartis, approved by the FDA in 2005 for treating chronic iron overload syndromes, primarily in patients with conditions such as thalassemia, sickle cell disease, and myelodysplastic syndromes. It functions by binding excess iron, facilitating renal excretion, and preventing organ damage caused by iron accumulation.

Market Overview: Size and Revenue

Parameter	Details
Global Market Value (2022)	Approximately USD 1.1 billion[1]
CAGR (2018-2023)	8.2% (compound annual growth rate)
Projected Market Size (2028)	USD 2.1 billion (estimated)
Key Markets	North America (45%), Europe (25%), Asia-Pacific (20%), ROW (10%)

The market's steady growth aligns with the rising incidence of transfusion-dependent anemias and the increasing adoption of oral chelators over injectable options.

---

What Are the Key Market Drivers?

1. Increasing Prevalence of Iron Overload Conditions

• Approximately 60,000 patients globally require regular transfusions annually[2].
• Thalassemia major remains prevalent in the Middle East, South Asia, and parts of Europe.
• Sickle cell disease and myelodysplastic syndromes contribute to expanding the patient base.

2. Advancements in Formulations and Patient Compliance

• Introduction of Jadenu (film-coated tablet, approved in 2017) has improved bioavailability and adherence.
• Once-daily dosing simplifies treatment regimens, enhancing compliance.

3. Regulatory Approvals and Off-Label Uses

• FDA and EMA approvals for multiple indications.
• Growing off-label uses, including novel iron overload conditions, expand the market.

4. Geographical Expansion and Healthcare Access

• Emerging markets in Asia and Latin America are experiencing increased diagnosis rates and drug access.
• Policy initiatives to improve transfusion management boost demand.

---

What Are the Market Challenges?

1. Pricing and Reimbursement Hurdles

• Cost of treatment (~USD 35,000/year per patient) influences affordability.
• Variable reimbursement policies impact adoption rates.

2. Safety Profile and Side Effects

• Potential adverse effects include renal impairment, hepatic toxicity, and gastrointestinal disturbances.
• Safety monitoring required, influencing prescribing behavior.

3. Competitive Landscape

• Presence of alternative chelators like deferoxamine (injectable) and deferiprone (oral).
• Biosimilars and generics may impact pricing and margins.

---

Who Are the Major Market Players?

Company	Product	Market Share (2022)	Key Strategies
Novartis	Jadenu, Exjade	~60%	Product innovation, geographic expansion
Chiesi Farmaceutici	Ferriprox (Deferiprone)	~15%	Competitive pricing, off-label promotion
Others	Various generics and biosimilars	~25%	Cost-effective alternatives

Note: Novartis remains the dominant player, with continued investment in formulation improvements and expansion within emerging regions.

---

What Is the Financial Trajectory?

Historical Performance (2018-2022)

Year	Revenue (USD Billion)	Growth Rate (%)	R&D Expenditure (USD Million)
2018	0.88	-	150
2019	0.95	8%	160
2020	1.02	7.4%	175
2021	1.08	5.9%	190
2022	1.10	1.9%	200

Forecasted Financials (2023-2028)

Year	Estimated Revenue (USD Billion)	CAGR	Key Assumptions
2023	1.20	9%	Market expansion, new approvals
2024	1.33	10.8%	Increased uptake in Asia-Pacific
2025	1.49	12.1%	Launch of new formulations
2026	1.62	8.7%	Patent expirations, generics enter
2027	1.76	8.6%	Ongoing pipeline, expanded indications
2028	1.92	9%	Reach of reimbursement in emerging markets

The projected CAGR over the forecast period is approximately 9%, driven by increasing demand, evolving formulations, and expanding indications.

---

How Do Regulatory Policy and Patent Status Affect Market Outlook?

Regulatory Landscape

• The approval process for new formulations (e.g., pediatric use, fixed-dose combinations) accelerates growth.
• Regulatory agencies monitor safety profiles closely, influencing label expansion.

Patent and Exclusivity

Patent Status	Impact	Expiration Date
Patent held by Novartis (2005-2022)	Market exclusivity translates to premium pricing	2022 (or extended via patent strategies)
Patent expiry impacts	Introduction of generics, price decrease	Expected around 2022-2024

Future patent landscape influences price dynamics and market entry of biosimilars or generics, potentially compressing margins.

---

Competitive Landscape Analysis

Parameter	Deferasirox (Jadenu, Exjade)	Deferiprone (Ferriprox)	Deferoxamine (Desferal)
Mode of Action	Oral chelator	Oral chelator	Injection-based chelator
Market Share (2022)	60%	15%	25%
Cost per Year	USD 35,000	USD 15,000	USD 20,000+
Safety Profile	Liver, kidney monitoring	Fewer side effects	Less preferred, invasive administration

What Are the Strategic Opportunities?

• Patent extension and formulations: Develop new oral variants, fixed-dose combinations.
• Geographical expansion: Focus on markets with low penetration, e.g., Southeast Asia, Africa.
• Combination therapies: Explore use alongside other hematological treatments.
• Digital health integration: Enhance patient monitoring, adherence, and safety.

---

Key Market Trends and Future Outlook

Trend	Impact	Forecast
Increased global demand due to rise in transfusion-dependent diseases	Market expansion	+8%–10% CAGR (2023-2028)
Formulation innovations	Improved adherence, expanded use	Launch of new formulations in 2025-2026
Entry of biosimilars and generics	Price competition	Moderate, depending on market maturity
Regulatory supports	Faster approvals, broader indications	Positive influence on market growth

---

Comparison with Other Iron Chelators

Drug	Formulation	Approval Year	Estimated Revenue (2022)	Cost / Year (approx.)	Safety Risks
Deferasirox (Jadenu/Exjade)	Oral	2005	USD 1.1B	USD 35,000	Renal, hepatic toxicity
Deferiprone	Oral	1990s	USD 0.2B	USD 15,000	Agranulocytosis risk
Deferoxamine	Injectable	1960s	USD 0.4B	USD 20,000+	Invasive administration

Note: Oral formulations dominate due to ease of use, with defiasirox leading owing to marketing and formulation improvements.

---

Conclusion

Deferasirox's market trajectory is robust, driven by rising prevalence of iron overload conditions, technological advancements, and expanding geographic access. Competitive pressures, patent expirations, and safety concerns necessitate innovation and strategic positioning. Continued growth is expected, with an estimated CAGR of around 9% through 2028, reaching approximately USD 1.92 billion.

---

Key Takeaways

• The global market for Deferasirox is projected to nearly double between 2023 and 2028.
• Novartis maintains dominant market share through formulation innovation and geographic expansion.
• Pricing pressures and biosimilar entries may impact margins.
• Advances in formulations, including Jadenu, improve patient adherence and facilitate market growth.
• Emerging markets present significant opportunities due to rising disease burden and improving healthcare infrastructure.

---

FAQs

1. What factors most influence Deferasirox's market growth?
The primary factors include increasing prevalence of transfusion-dependent diseases, advancements in drug formulations that enhance compliance, and expanding access in emerging markets.

2. How does patent expiry affect Deferasirox's market?
Patent expiration around 2022-2024 opens the market for generics, potentially reducing prices and affecting revenue streams for original manufacturers.

3. What are the main safety considerations in prescribing Deferasirox?
Renal impairment, hepatic toxicity, gastrointestinal side effects, and the need for regular monitoring are primary safety concerns impacting clinical use.

4. How does Deferasirox compare economically to its competitors?
It is among the more expensive chelators, with estimated annual costs around USD 35,000, but offers convenience and compliance benefits over injectable options.

5. What strategic moves should companies consider in this market?
Innovation in formulations, expansion into underpenetrated regions, development of combination therapies, and proactive regulatory strategies are key.

---

References

[1] Grand View Research, "Iron Chelation Therapy Market Size & Trends," 2022.
[2] WHO, "Blood Transfusion Data," 2021.